Search

Researchers from Curtin University in Australia have developed a new method for simultaneously analyzing the antidiabetic drugs metformin, glipizide, and gliclazide using HPLC. These drugs, commonly used to control blood glucose levels, have also shown potential for non-diabetic pharmacological purposes. The study focused on quantifying metformin uptake by auditory cells and its protective role under hyperglycemic conditions. The research provides insights into the pharmacokinetics and therapeutic monitoring of these agents, offering a precise and rapid analytical method for clinicians. [Extracted from the article]

A recent study conducted at the University of Washington examined the impact of insulin sensitivity and beta-cell function on glycemic outcomes in response to dual therapy for diabetes. The study found that higher insulin sensitivity and C-peptide responses were associated with better initial treatment responses and lower risk of glycemic failure. These associations varied depending on the type of treatment received, with sitagliptin showing greater impact on initial HbA(1c) reduction compared to other therapies. The research, which has been peer-reviewed, provides valuable insights into the effectiveness of different antidiabetic agents in managing diabetes. [Extracted from the article]

Researchers from Duquesne University conducted a study on the physical stability of amorphous solid dispersions of antidiabetic agents, specifically bromopropamide, chlorpropamide, and tolbutamide, in interaction with polyvinylpyrrolidone vinyl acetate copolymer (PVPVA). The research found that the addition of bromopropamide to PVPVA resulted in strong coexistent hydrogen and halogen bonding interactions, leading to different crystallization tendencies among the drug-polymer systems. The study concluded that bromopropamide exhibited the highest thermal properties and crystallization tendency among the analogues. This research has been peer-reviewed and provides valuable insights into the implications of coexistent halogen and hydrogen bonds on the physical stability of drug-polymer systems. [Extracted from the article]

Researchers at Gifu University in Japan have found that glyburide, a medication used to manage diabetes, may suppress inflammation-related colorectal tumorigenesis by inhibiting the NLRP3 inflammasome. The study, funded by Sgh Cancer Research and Grants-in-aid For Scientific Research Jsps Kakenhi, showed that both NLRP3 deficiency and glyburide treatment reduced colitis-related tumorigenesis in mice. These findings suggest that glyburide could potentially be used as a chemopreventive agent for colitis-related colorectal cancer. [Extracted from the article]

A recent study conducted at the University of Ioannina in Greece focused on the analysis of 10 anti-diabetic drugs in environmental water samples using Fabric Phase Sorptive Extraction (FPSE) coupled with high-performance liquid chromatography. The research highlighted the detection of various anti-diabetic drugs, such as metformin, dapagliflozin, and glimepiride, in different water sources, including surface water, wastewaters, and hospital effluents. The study emphasized the importance of investigating the presence of these drugs in environmental samples due to their emerging contaminant status. For more details, the full article can be accessed through the publisher, MDPI AG. [Extracted from the article]

A recent report discusses research conducted in Porto Alegre, Brazil on the effects of gliclazide, a sulfonylurea compound, on exercise performance and muscle recovery. The study involved 10 healthy resistance-trained adults who were randomized to receive either a placebo or gliclazide before two exercise sessions. The results showed that gliclazide did not enhance performance during the exercise sessions but did promote faster muscle recovery. However, it also caused a decrease in blood glucose levels, which could have long-term effects on glucose metabolism. The study was registered in ClinicalTrials.gov and was not funded. [Extracted from the article]

A study conducted by researchers at AlFaisal University in Riyadh, Saudi Arabia, examined the incidence of adverse effects among diabetic patients treated with the antidiabetic drug glipizide. Glipizide is commonly prescribed for type II diabetes following a kidney transplant. The study found that adverse effects were more common in female patients and in patients under 40 years of age. The researchers recommend considering age and sex in future studies to improve treatment outcomes and reduce adverse events. They also suggest genetic screening before administering the medication and routine follow-up. [Extracted from the article]

A recent study conducted by researchers at the Medical University of Silesia in Katowice, Poland, explored the interaction between two antidiabetic agents, glipizide and losartan, and human serum albumin (HSA). The study found that the glycation of HSA significantly altered its structure and reduced the binding affinity of glipizide and losartan to the protein. The researchers also observed that the presence of one drug in the albumin complex could lead to competitive binding or displacement of the other drug. The study highlights the importance of closely monitoring patients who are co-administered these drugs to ensure optimal therapeutic efficacy and safety. [Extracted from the article]

A recent study conducted at I.M. Sechenov First Moscow State Medical University explores the use of gliclazide modified release (MR) in the treatment of type 2 diabetes mellitus. The study highlights the unique features of gliclazide MR, including its high hypoglycemic activity, low risk of hypoglycemia, neutral effect on weight, and proven nephroprotective properties. The research concludes that gliclazide MR has a place in modern treatment strategies for patients with type 2 diabetes, as indicated by international and national clinical guidelines. For more information, the full study can be accessed through the provided link. [Extracted from the article]

The article focuses on a clinical trial, NCT06570980, that compares the cost-effectiveness of Sulfonylureas and DPP4 inhibitors in combination with Metformin for Type 2 diabetes. Topics include evaluating glycemic control and clinical outcomes, analyzing direct medical costs, and comparing the incremental cost-effectiveness ratios (ICERs) of the two drug combinations.

A recent study conducted by researchers at the University of Petra in Amman, Jordan, explored the correlation between the blood levels of metformin and glimepiride, two antidiabetic agents, and genetic polymorphism in diabetic patients. The study involved 106 patients with type 2 diabetes and found that patients with a specific genetic polymorphism had higher levels of metformin in their blood. The researchers suggest that genotype-guided drug therapy could potentially enhance drug efficacy and minimize toxicity. This research provides valuable insights into the therapeutic monitoring of antidiabetic agents and their impact on diabetic patients. [Extracted from the article]

A recent study conducted at Mayo Clinic Florida has found that the illicit drug market sometimes substitutes sulfonylureas, a type of antidiabetic medication, for benzodiazepines like Valium due to their similar appearance and low cost. This can lead to hypoglycemia, a condition characterized by low blood sugar levels. The study presented a case of a 33-year-old patient who experienced hypoglycemia after ingesting what she believed to be Valium. Laboratory tests confirmed exposure to sulfonylureas. The researchers concluded that when severe hypoglycemia is diagnosed in unresponsive patients suspected of taking illicit drugs, sulfonylurea substitution or drug contamination should be considered. [Extracted from the article]

A recent study conducted at Thiruvalluvar University in Tamil Nadu, India, focused on the encapsulation of the antidiabetic drug glimepiride with chitosan nanoparticles. The researchers aimed to provide better treatment options for individuals with type 2 diabetes mellitus. The study found that the encapsulated glimepiride-chitosan nanoparticles had a high encapsulation efficiency of 91.4% and demonstrated sustained release of the drug over 32 hours. Additionally, the nanoparticles showed inhibitory potential against enzymes involved in carbohydrate breakdown. The researchers believe that this controlled and prolonged release could improve patient compliance and glucose level control. [Extracted from the article]

A recent report from researchers at Gupta College of Technological Science in West Bengal, India discusses the development, characterization, and evaluation of polymer-based hydrogel membrane patches for the intestinal delivery of gliclazide, a medication used in the management of type-II diabetes mellitus. The study found that the hydrogel membrane patches had satisfactory properties such as drug content, thickness, and moisture content. In vitro and ex vivo studies demonstrated sustained release of gliclazide and good mucoadhesion of the patches, suggesting their potential effectiveness in diabetes management. The research has been peer-reviewed and more information can be obtained from the authors. [Extracted from the article]

A recent study conducted by the Department of Pharmaceutics focused on improving the solubility and dissolution of the antidiabetic agent glimepiride. Glimepiride is used to lower blood sugar levels in individuals with type 2 diabetes, but its low aqueous solubility poses a challenge. The researchers aimed to increase its solubility by using hydrotropic agents instead of volatile organic solvents. The study found that the use of hydrotropic agents significantly increased the solubility and drug release of glimepiride, suggesting that this approach could enhance the solubility of poorly water-soluble drugs. [Extracted from the article]

Researchers at Indira Gandhi National Tribal University in India have developed novel nanocarriers using modified guar gum to control type 2 diabetes. The modified guar gum, called CMGGOSA-I, was found to be non-toxic and self-assembled in water to form nanocarriers. These nanocarriers enhanced the solubility of glimepiride, a drug used to treat diabetes, and released it over a period of more than 24 hours. In a diabetic rat model, the nanocarriers demonstrated better anti-diabetic activity compared to pure drug suspensions. This research shows promise for the development of controlled drug release systems for type 2 diabetes treatment. [Extracted from the article]

A recent study conducted by researchers at the University of Padova compared the effectiveness and cost-effectiveness of different drugs for the treatment of type 2 diabetes. The study found that newer diabetes drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1-RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i), and dipeptidyl peptidase-4 inhibitors (DPP-4i), were more effective and cost-effective as second-line therapy compared to sulfonylureas (SU). The research included a population-based retrospective cohort study of over 22,000 patients with diabetes in Lombardy, Italy. The findings suggest that newer diabetes drugs may be better options for the treatment of type 2 diabetes. [Extracted from the article]

Researchers from King Khalid University have published a report on their recent chemistry research. The study focuses on the design, synthesis, and evaluation of novel sulfonylurea and sulfonylthiourea compounds as inhibitors of certain enzymes involved in nucleotide metabolism. The researchers found that some of these compounds showed promising inhibitory activity against the enzymes tested, as well as anticancer activity against breast cancer cells. Importantly, the compounds were not found to be toxic to normal cells. This research provides valuable insights into potential therapeutic targets for various diseases. [Extracted from the article]

A study conducted by Boehringer Ingelheim International GmbH found that the use of empagliflozin, a medication for type 2 diabetes, is not associated with an increased risk of acute pancreatitis. The study analyzed data from two large US claims databases and compared patients newly prescribed empagliflozin to those prescribed sulfonylurea. After a mean follow-up of approximately 6 months, the incidence rates of acute pancreatitis were similar between the two groups. These findings provide additional evidence regarding the safety of empagliflozin for the treatment of type 2 diabetes. [Extracted from the article]

A study conducted by researchers at Qingdao University in China has found that the sulfonylurea drug gliquidone, commonly used to treat type 2 diabetes, may have potential for the therapy of Brugada syndrome. Brugada syndrome is an inherited disease characterized by abnormal heart rhythms. The researchers discovered that gliquidone inhibits certain channels in the heart responsible for the initial phase of action potential repolarization. This finding suggests that gliquidone could be repurposed as a treatment for Brugada syndrome. [Extracted from the article]

A clinical trial, NCT06423729, has been launched to evaluate the effect of nicorandil on glycemic control and body weight in type 2 diabetic obese patients treated with sulfonylureas. The trial will assess changes in HbA1c levels, body weight, body mass index (BMI), and visceral adiposity index (VAI) over a period of 3 months. The study aims to determine the potential benefits of adding nicorandil to the treatment regimen of these patients. The trial is currently recruiting participants in Egypt and is expected to be completed by January 2025. [Extracted from the article]

A recent study explored a treatment strategy for spinal cord injury (SCI) that involves the administration of glibenclamide and diazoxide at different time intervals post-SCI. The goal was to determine if this approach could enhance sensory and motor function. The study found that the timed application of these drugs significantly improved locomotor function and mitigated the development of SCI-induced chronic pain. These findings suggest a promising treatment strategy for addressing SCI-induced dysfunction. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted at Ajman University in the United Arab Emirates focused on enhancing the solubility of the antidiabetic drug glipizide. The researchers used polyvinyl pyrrolidone (PVP) and polyethylene glycol (PEG) to prepare solid dispersions of glipizide. The results showed that formulations with higher concentrations of the polymer had enhanced solubility and dissolution rates compared to the pure drug. The researchers also optimized two solid dispersion formulations and formulated them into immediate-release tablets that passed all necessary tests. The study concluded that there was compatibility between the drug and the polymer based on characterization tests. [Extracted from the article]

A study conducted at the University of Rajshahi in Bangladesh has investigated the use of Gliclazide-loaded Aerosil 380 solid dispersion-based tablets with co-processed excipients for enhanced drug release. The tablets were formulated using a coprocessing strategy and were compared to leading marketed formulations. The results showed that the tablets with co-processed excipients had improved physicochemical properties and drug release rates compared to the marketed formulations. This research could lead to the development of more effective tablet solid dosage forms for drugs with low water solubility. [Extracted from the article]

Researchers at Curtin University in Bentley, Australia have developed a new drug reservoir using a composite bead loaded with gliclazide, a hypoglycemic agent. The bead was created through a process called ionic gelation, using acidified CaCl, chitosan, and tetraethylorthosilicate as a crosslinker. The researchers optimized the pharmaceutical formula of the bead, which exhibited controlled release of gliclazide and compatibility with skeletal muscle drug delivery. The study concluded that the bead showed high cell viability and has potential for use in drug therapy. [Extracted from the article]

A study conducted at Pondicherry University in India explored the impact of combining the natural compound mangiferin with the oral hypoglycemic drugs metformin and gliclazide on diabetic neuropathy. Diabetic neuropathy is a complication of diabetes characterized by neuronal damage and neuropathic pain. The study found that the combination of mangiferin with metformin and gliclazide delayed pain perception in rats and showed a synergistic effect on antioxidant enzyme levels in the brain tissue. These findings suggest that the combination of mangiferin with these commonly used drugs may help alleviate the symptoms of diabetic complications. [Extracted from the article]

A recent study conducted at Massachusetts General Hospital compared the risk of gout and recurrent flares between patients with type 2 diabetes (T2D) who were prescribed sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and those who were prescribed sulfonylureas. The study found that patients who initiated SGLT2i had a lower incidence of gout compared to those who initiated sulfonylureas. SGLT2i use was also associated with fewer recurrent flares among patients with gout and a lower risk of major adverse cardiovascular events. These findings suggest that SGLT2i may be a beneficial treatment option for patients with T2D who are at risk for or already have gout. [Extracted from the article]

A recent study conducted by researchers at Symbiosis International University in India analyzed the cost variation among different brands of oral hypoglycemic drugs available in the Indian market. The study found that there is a wide variation in the prices, cost ratio, and cost variation of these drugs. The researchers collected data from October 2020 to January 2021 and calculated the difference between the maximum and minimum costs for each drug. The study provides valuable information for physicians in prescribing the most economical treatment for diabetes. [Extracted from the article]

Researchers at the National Autonomous University of Mexico (UNAM) have conducted a study on the stability of inclusion complexes of chlorpropamide and cyclodextrin using molecular dynamics simulations. The study found that the complexes were stable and that the stabilization was driven by hydrophobic interactions between cyclodextrin and chlorpropamide. The research also revealed a correlation between the electron density contributions to weak interactions and the glucopyranose units in each cyclodextrin. The findings suggest that beta-type cyclodextrins are important for creating reliable inclusion complexes, which could have potential applications in molecular encapsulation and drug delivery systems. [Extracted from the article]

A study conducted by researchers at the University of Jordan explores the impact of glycosylated sulfonylureas on the insulin signaling pathway. The study utilized in vitro and ex vivo models to evaluate the gene expression of insulin-dependent pathways. The results showed that the glycosylated sulfonylurea analogues tested exhibited a significant increase in the gene expression of insulin-dependent pathways, suggesting their potential as therapeutic anti-diabetic drugs. The study highlights the importance of skeletal muscle in insulin-stimulated glucose uptake and its role in the pathogenesis of type 2 diabetes mellitus. [Extracted from the article]

A recent study conducted in Tamil Nadu, India, by researchers from the School of Advanced Sciences focuses on the development of an interpenetrating polymer network (IPN) hydrogel bead as a drug carrier system for extended release of the antidiabetic medication glipizide. The researchers used a combination of hydrophilic polymers and a crosslinking agent to create the hydrogel bead. The study found that increasing the concentration of xanthan gum and the crosslinking agent resulted in a slower drug release, extending it to 14 hours. Overall, the study demonstrates the potential of the IPN drug carrier system for controlled and extended release of short-acting oral sulfonylurea medications. [Extracted from the article]

A recent study conducted at Riphah International University in Lahore, Pakistan, focused on the development and characterization of polymeric nanoparticles (PNPs) for the enhancement of the dissolution and solubility of the antidiabetic drug glimepiride (GLM). The researchers used chitosan, polyvinyl pyrrolidone, and Tween 80 as components of the PNPs, and tri-polyphosphate as a crosslinking agent. The PNPs showed promising results in terms of encapsulation efficiency, particle size, morphology, thermal behavior, and dissolution profile. The study suggests that these PNPs could be used as carriers for oral drug delivery of GLM. [Extracted from the article]

This document provides information about a clinical trial, NCT06222476, that aims to investigate the effectiveness of dorzagliatin, a new antidiabetic drug, in combination with metformin for the treatment of type 2 diabetes mellitus. The trial will involve 106 participants with type 2 diabetes and will assess the impact of the drug combination on various outcomes, including glycemic control and kidney function. The study is expected to be completed by June 2026. The document also includes recruitment information and administrative details about the trial. [Extracted from the article]

A study conducted at the University of Florence in Italy compared the effectiveness of dry-ball and wet-bead nano-milling methods in producing nanocrystals of glyburide with improved dissolution properties. The researchers used a full factorial design to evaluate the impact of critical factors such as milling time, milling speed, ball/bead volume, and drug amount on particle size and dissolution rate. The study found that the wet-method with the addition of a solubilizing polymer resulted in a higher percentage of dissolved drug at 10 minutes compared to the dry-method. Solid-state studies also indicated that the dry-milling process affected the drug's crystallinity and dissolution rate. This research has been peer-reviewed and published in the Journal of Drug Delivery Science and Technology. [Extracted from the article]

A study conducted by researchers at Annamalai University in Chidambaram, India, explored the solubility of Gliclazide (GCL), a drug commonly used to reduce hyperglycemia in diabetic patients. The researchers used two different anionic micellar solutions with varying hydrophobic chain lengths to solubilize GCL. Their findings revealed that the longer hydrophobic chain length was more effective in solubilizing GCL and improving its properties. The study offers a novel drug formulation for GCL and provides insights into its solubility. [Extracted from the article]

A study conducted at the Federal University Rio Grande do Norte in Natal, Brazil, has investigated the solid-state properties of two antidiabetic drugs, acetohexamide and tolazamide. The researchers used Density Functional Theory (DFT) to study the electronic, optical, and vibrational properties of the crystals, and performed Hirshfeld surface analysis to better understand their crystalline packing. The study found that acetohexamide had an indirect band gap of 2.49 eV, while tolazamide had a direct band gap of 3.25 eV. Both drugs exhibited strong optical absorption in the ultraviolet region. The research also interpreted the IR and Raman spectra of the drugs. This study was supported by Brazilian research agencies CAPES (PNPD), CNPQ, and FAPEAL. [Extracted from the article]

A recent study conducted by researchers at the University of Lille in France has found that rare pathogenic variants in the GLIS3 gene increase the risk of type 2 diabetes. The study sequenced GLIS3 in over 5,000 individuals and identified 105 rare variants, 18 of which were classified as pathogenic or likely pathogenic. These variants were found to be more prevalent in individuals with type 2 diabetes and were associated with decreased activation of the INS promoter. Interestingly, all carriers of these variants with type 2 diabetes were found to be sensitive to oral sulfonylureas. The study suggests that these rare GLIS3 variants contribute to type 2 diabetes risk and may have a direct effect on beta cell function. [Extracted from the article]

A study conducted by researchers at the University of Sao Paulo in Brazil focused on the measurement uncertainty that arises from the sampling and analytical steps of the dissolution test for glyburide tablets, which are used in antidiabetic therapy. The dissolution test is an important technique in pharmaceutical research to assess the release of a drug from a dosage form. The study found that the dissolution test of glyburide tablets had high sampling uncertainty and did not meet the specified limits, likely due to the low solubility of glyburide. The research provides insights for pharmaceutical industries to optimize their quality control processes and ensure the efficacy and safety of their products. [Extracted from the article]

A clinical trial, NCT06168812, is currently recruiting participants to investigate the effectiveness and safety of glipizide in lowering blood sugar levels in individuals with pancreatic cancer. The trial aims to determine the impact of glipizide on mean interstitial glucose levels before and after initiation of the drug. The study is interventional, with a non-randomized allocation and a parallel assignment design. Participants in the trial will receive glipizide for up to 4 months and undergo continuous glucose monitoring. The trial is specifically focused on patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and hyperglycemia, and has eligibility criteria based on age, disease status, and previous treatments. The trial is being conducted by the Memorial Sloan Kettering Cancer Center and data from the trial may be shared with researchers. [Extracted from the article]

Researchers from the University of Rajshahi have conducted a study on gliclazide therapy, aiming to develop improved tablet formulations for the drug. The researchers utilized solid dispersions (SDs) and co-processed excipients composite to enhance the release rate of gliclazide, which has poor water solubility. Through various tests and analyses, the researchers found that the tablet batches containing the co-processed composite were the most effective formulations, with a significantly higher drug release compared to currently marketed products. This approach could be beneficial for creating solid dosage forms for drugs with low solubility in water. [Extracted from the article]

A recent study conducted by researchers at the National Institute of Pharmaceutical Education and Research in Bihar, India, focused on the use of quantitative structure-retention relationship (QSRR) models to predict the retention time of anti-diabetic drugs in the HPLC method development process. The study developed 11 QSRR models, with models 4 and 5 based on support vector machines (SVM) showing the best predictive ability. The experimental retention time of certain anti-diabetic drugs was verified, and a new HPLC method was optimized for the simultaneous analysis of pioglitazone and glimepiride. The method demonstrated specificity, robustness, and acceptable accuracy. [Extracted from the article]

A recent study conducted at Believers Church Medical College Hospital in Kerala, India, explored the effects of anti-diabetic drugs on cognitive impairment in individuals with type 2 diabetes (T2DM). The researchers constructed a T2DM protein network and identified the interactomes of metformin and glimepiride, two commonly used anti-diabetic drugs. They found that glimepiride effectively increased brain-derived neurotrophic factor (BDNF), which could benefit T2DM patients with cognitive deterioration. This research provides valuable insights into the potential cognitive benefits of glimepiride for individuals with T2DM. [Extracted from the article]

A new study conducted by researchers at Gujarat Technological University in India has developed a high-performance thin-layer chromatography method for the simultaneous quantification of Glimepiride and 3-acetyl-11-keto-beta-boswellic acid in a formulation. The method was found to be accurate, precise, reproducible, robust, and specific. The study utilized a fractional factorial design to evaluate the small differences in independent variables. This research provides valuable insights into the development of antidiabetic agents and may be of interest to those studying pharmaceuticals and health and medicine. [Extracted from the article]

Keywords: Amaryl Therapy; Antidiabetic Agents; Drugs and Therapies; Glimepiride Therapy; Health and Medicine; Pharmaceuticals; Sulfonylureas EN Amaryl Therapy Antidiabetic Agents Drugs and Therapies Glimepiride Therapy Health and Medicine Pharmaceuticals Sulfonylureas 3165 3165 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on antidiabetic agents are discussed in a new report. Amaryl Therapy, Antidiabetic Agents, Drugs and Therapies, Health and Medicine, Pharmaceuticals, Sulfonylureas, Glimepiride Therapy. [Extracted from the article]

Antidiabetic Agents, Antihyperglycemics, Biguanides, Biomarkers, Cardiology, Clinical Research, Clinical Trials and Studies, Diabetes Mellitus, Diagnostics and Screening, Drugs and Therapies, Endocrine System Diseases and Conditions, Endocrinology, Glimepiride Therapy, Glucose Metabolism Disorders, Health and Medicine, Hypoglycemic Agents, Insulin Dependent Diabetes Mellitus, Metabolic Diseases and Conditions, Metformin, Metformin Therapy, Non-Insulin Dependent Diabetes Mellitus, Non-Sulfonylureas, Nutritional and Metabolic Diseases and Conditions, Nutritional and Metabolic Diseases and Conditions - Type 2 Diabetes, Peptide Hormones, Peptide Proteins, Pharmaceuticals, Proinsulin, Sulfonylureas, Type 2 Diabetes, Vildagliptin Therapy All enrolled patients will be divided into two groups; both groups will be patients who are uncontrolled and already on metformin, group I will receive vildagliptin as an add-on therapy while group II will receive glimepiride. [Extracted from the article]